GSK and IDEAYA partner in synthetic lethality
The deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes
Read More
Tag: synthetic lethality
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
